RxDoctor Payments Data

Thi Dang, MD

Cardiovascular Disease · Torrance, CANPI 1235417411

Payments from drug & device makers

$712in general payments, 2019–2025

Across 27 payments — averaging $26.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$253
  • E.r. Squibb & Sons, L.L.C.$118
  • Pfizer$102
  • Boehringer Ingelheim$86
  • Medtronic$44
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$36
  • plus $73 from 4 others

What the payments were for

  • Food & beverage$51472%
  • Education$19828%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$712 in reported general payments places this provider in the 30th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$257,439
Medicare patients
1,234
Services billed
3,240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban374$504,741
XareltoRivaroxaban80$98,960
EntrestoSacubitril/Valsartan65$61,534
JardianceEmpagliflozin39$45,680
WegovySemaglutide15$19,371
Praluent PenAlirocumab13$7,956
Amiodarone Hcl34$5,057
Metoprolol Succinate270$4,231
Ranolazine ErRanolazine12$3,988
Diltiazem 24hr Er (Cd)Diltiazem Hcl56$3,663
Flecainide Acetate37$2,733
Atorvastatin Calcium205$2,554
Losartan Potassium145$1,718
Rosuvastatin Calcium94$1,631
Amlodipine Besylate166$1,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$102$504,741374 claims
NovartisEntresto$15$61,53465 claims
Boehringer IngelheimJardiance$86$45,68039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →